Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by the US FDA.
The company said that, to date, 37 of the 51 states provide fee-for-service Medicaid coverage for Ryoncil through Orphan Drug Lists or the medical exception process, representing 20 million people. The remainder will come online July 1, 2025, with mandatory coverage for 24 million. Commercial plans representing private payers and managed Medicaid have published policies, prior authorisation, and formulary lists in place for Ryoncil covering 84 million people. The company said this number does not include the medical exceptions policies for Ryoncil, which are in place with most commercial payers.
